Angiotensin blockade is associated with early graft dysfunction after live donor renal transplantation

Transplantation

Volumn 89, Issue 6, 2010, Pages 707-709

  Stevens, Kathryn K ^a   Patel, Rajan K ^a,b   Clancy, Marc ^a   Jardine, Alan G ^a,b  

^a WESTERN INFIRMARY   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

ACE inhibitor; Angiotensin receptor blocker; Delayed graft function; Renal transplant

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ADOLESCENT; ADULT; AGED; ARTICLE; CREATININE BLOOD LEVEL; FEMALE; HEMODIALYSIS; HEMODYNAMICS; HUMAN; KIDNEY DONOR; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PRIORITY JOURNAL; RENAL GRAFT DYSFUNCTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ADOLESCENT; ADULT; AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BIOLOGICAL MARKERS; CREATININE; DELAYED GRAFT FUNCTION; FEMALE; HUMANS; KIDNEY TRANSPLANTATION; LIVING DONORS; MALE; MIDDLE AGED; PILOT PROJECTS; RENAL DIALYSIS; RENIN-ANGIOTENSIN SYSTEM; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77949892096     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181c892f2     Document Type: Article

References (10)

1. Tarantino A. Why shouldwe implement living donation in renal transplantation? Clin Nephrol 2000; 53(suppl): 55.
2. Wolfe RA, Ashby VB, Milford EL, et al. Comparison of mortality in all patients on dialysis awaiting transplantation and recipients of a first cadaveric transplant. N Engl J Med 1999; 341: 1725.
3. Schnuelle P, Lorenz D, Trede M, et al. Impact of renal cadaveric transplantation on survival in end stage renal failure: Evidence for reduced mortality risk compared with hemodialysis during long term follow up. J Am Soc Nephrol 1998; 9: 2135.
4. Halloharan PF, Hunsicker LG. Delayed graft function: State of the art, November 10-11, 2000. Summit meeting, Scottsdale, Arizona, USA. Am J Transplant 2001; 1: 115.
5. Yarlagadda SG, Coca SG, Formica RN Jr, et al. Association between delayed graft function and allograft and patient survival: A systematic review and meta-analysis. Nephrol Dial Transplant 2009; 24: 1039.
6. http://www.gro-scotland.gov.uk/statistics. Accessed July 2009.
7. Weir MR, Henrich WL. Theoretical basis and clinical evidence for differential effects of angiotensin-converting enzyme inhibitors and an-giotensin II receptor subtype 1 blockers. Curr Opin Nephrol Hypertens; 2000; 9: 403.
8. Maldonado-MartinezM.Hypertensioninend-stage renal disease.Kidney Int 1998; 54: S67.
9. Israili ZH. Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension. J Hum Hypertension 2000; 14(suppl 1): S73.
10. Song JC, White CM. Clinical pharmacokinetics and selective pharma-codynamics of new angiotensin converting enzyme inhibitors: An update. Clin Pharmacokinet 2002; 41: 207.